Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.56 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.56 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | LAP3 | P28838 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3422138 | 1.00 | DPP4 (0.56) | DPP4DPP8DPP9FOLH1KMT2A | |
| Leucine SCHEMBL14126315 | 0.96 | DPP4 (0.52) | DPP4DPP8DPP9FOLH1KMT2A | |
| SCHEMBL31121653 | 0.94 | DPP4 (0.51) | DPP4DPP8DPP9FOLH1KMT2A | |
| SCHEMBL29777822 | 0.94 | DPP4 (0.51) | DPP4DPP8DPP9FOLH1KMT2A | |
| SCHEMBL30974319 | 0.93 | BACE1 (0.53) | DPP4DPP8DPP9FOLH1KMT2A | |
| SCHEMBL29381184 | 0.93 | DPP4 (0.50) | DPP4DPP8DPP9FOLH1KMT2A | |
| SCHEMBL30060796 | 0.93 | DPP4 (0.52) | DPP4DPP8DPP9FOLH1KMT2A | |
| SCHEMBL31199055 | 0.92 | BACE1 (0.55) | DPP4DPP8DPP9FOLH1CTSD | |
| SCHEMBL1674769 | 0.90 | FOLH1 (0.50) | DPP4DPP8DPP9FOLH1KMT2A | |
| SCHEMBL28556186 | 0.89 | DPP4 (0.58) | DPP4DPP8DPP9FOLH1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695413-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | claimed |
| CN-118897023-B | Method for directly measuring alpha and gamma-glutamyl peptide in skeletal muscle by using LC-MS and isotope dilution assay | 中国农业科学院北京畜牧兽医研究所 | 2025-03-25 | — | — | CN | claimed |
| CN-119530123-A | Low-sodium salt-reducing and freshness-increasing metaplasia and preparation method and application thereof | 内蒙古科拓生物有限公司 | 2025-02-28 | — | — | CN | claimed |
| US-20250027938-A1 | METABOLIC SIGNATURE FOR PREDICTION OF MUCOSAL INFLAMMATION AND MICROBIAL COMPOSITION | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-01-23 | — | — | US | claimed |
| CN-119291059-A | Screening method for metabolic markers for distinguishing non-colorectal cancer diseases from colorectal cancer and application of screening method | 哈尔滨脉图精准技术有限公司 | 2025-01-10 | — | — | CN | claimed |
| CN-118897023-A | Method for directly measuring alpha and gamma-glutamyl peptide in skeletal muscle by using LC-MS and isotope dilution assay | 中国农业科学院北京畜牧兽医研究所 | 2024-11-05 | — | — | CN | claimed |
| WO-2024216031-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-10-17 | — | — | WO | claimed |
| WO-2024132726-A1 | SERUM PEPTIDE PATTERNS FOR DIAGNOSTICS OF ACUTE ISCHEMIC STROKE IN HUMANS AND DIFFERENTIAL DIAGNOSIS OF ACUTE ISCHEMIC STROKE FROM INTRACRANIAL HEMORRHAGIC STROKE | UNIWERSYTET GDANSKI (PL) | 2024-06-27 | — | — | WO | claimed |
| EP-4370919-A1 | METABOLIC SIGNATURE FOR PREDICTION OF MUCOSAL INFLAMMATION AND MICROBIAL COMPOSITION | Imperial College Innovations Limited (GB) | 2024-05-22 | — | — | EP | claimed |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | IMMUNOGEN, INC. (US) | 2023-03-30 | — | — | US | claimed |
| US-20150377910-A1 | Biomarkers for Fatty Liver Disease and Methods Using the Same | METABOLON, INC. | 2015-12-31 | — | — | US | claimed |
| EP-2546649-B1 | Biomarkers for fatty liver disease and methods using the same | METABOLON INC (US) | 2015-02-25 | — | — | EP | claimed |
| WO-2013188333-A1 | BIOMARKERS RELATED TO NEPHROTOXICITY AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-12-19 | — | — | WO | claimed |
| WO-2013155528-A2 | METHODS FOR REDUCING BRAIN INFLAMMATION, INCREASING INSULIN SENSITIVITY, AND REDUCING CERAMIDE LEVELS | FASGEN, INC. (US) | 2013-10-17 | — | — | WO | claimed |
| EP-2546649-A2 | Biomarkers for fatty liver disease and methods using the same | Metabolon Inc. (US) | 2013-01-16 | — | — | EP | claimed |
| EP-2227689-B1 | BIOMARKERS FOR FATTY LIVER DISEASE AND METHODS USING THE SAME | METABOLON INC (US) | 2012-12-26 | — | — | EP | claimed |
| US-20100279956-A1 | Biomarkers For Fatty Liver Disease And Methods Using The Same | METABOLON, INC. | 2010-11-04 | — | — | US | claimed |
| US-5863937-A | PEPTIDE CONJUGATED COMPOUND AS FUNGICIDES, BACTERICIDES, MICROBIOCIDES TREATING CANDIDA ALBICANS INFECTION | BTG INTERNATIONAL LIMITED (GB) | 1999-01-26 | — | — | US | claimed |
| EP-0722456-A1 | ANTIFUNGAL COMPOSITIONS | BTG INTERNATIONAL LIMITED (GB) | 1996-07-24 | — | — | EP | claimed |
| WO-1995009867-A1 | ANTIFUNGAL COMPOSITIONS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1995-04-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | GABBR2, GABRB1, GABRB2 | DPP4 4586/4885DPP8 4829/4885DPP9 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.